Curated News
By: NewsRamp Editorial Staff
September 28, 2026
Redcare Pharmacy Raises 2026 Guidance on Strong Rx Momentum
TLDR
- Redcare Pharmacy raised 2026 revenue growth guidance to 16 to 18 percent, signaling strong momentum that investors can leverage.
- Redcare Pharmacy upgraded 2026 guidance due to 51 percent September Rx growth in Germany, with total revenue growth now 16 to 18 percent.
- Redcare Pharmacy's rising eRx NPS of 80 shows better customer satisfaction, helping more people access prescriptions conveniently and safely.
- Redcare Pharmacy raised its 2026 guidance again as German Rx revenue jumped 51 percent in September and eRx NPS hit 80.
Impact - Why it Matters
This news matters because it underscores the accelerating shift toward digital healthcare in Europe. Redcare Pharmacy's upward revision—its second this year—signals robust demand for online pharmacy services, particularly for prescription medications in Germany. The 51% year-on-year growth in Rx revenue in September, despite a tough comparison, demonstrates that customers are increasingly embracing e-prescriptions and digital pharmacy solutions. The rising eRx NPS score of 80 further indicates high satisfaction, which could drive sustained loyalty and market share gains. For investors, the raised guidance suggests stronger-than-expected financial performance, potentially boosting confidence in the company's growth trajectory. Moreover, as the leading online pharmacy in Europe with over 14 million active customers, Redcare's success highlights the broader trend of healthcare digitalization, which could pressure traditional brick-and-mortar pharmacies to innovate. Ultimately, this development benefits patients by expanding access to convenient, safe, and comprehensive pharmaceutical services.
Summary
Redcare Pharmacy N.V., the leading online pharmacy in Europe, has raised its full-year 2026 revenue guidance for the second time this year, driven by exceptional momentum in prescription (Rx) revenue in Germany. The company now expects Rx revenue in Germany to reach EUR 730 to 760 million, up from the previously guided EUR 680 to 720 million, representing growth of 45% to 51%. This upgrade follows preliminary figures showing Rx revenue grew 51% year-on-year in September and 56% in Q3, despite a high comparison base from the prior year when the current Rx bonus was introduced. Total revenue growth guidance for 2026 was also increased to 16% to 18%, from 15% to 17% previously, while non-Rx growth (10% to 12%) and adjusted EBITDA margin (2.5% to 3.0%) guidance remain unchanged.
CEO Olaf Heinrich attributed the strong performance to high customer satisfaction, noting that the eRx Net Promoter Score (NPS) rose 6 points year-on-year to 80 in August. While Rx revenue remained robust throughout the quarter, non-Rx revenue in Germany rebounded well in August and September after a softer July. The adjusted EBITDA margin remained flat quarter-on-quarter, benefiting from continued operating leverage. Redcare Pharmacy will publish its full Q3 2026 figures and host its quarterly conference call on October 29, 2026.
Founded in 2001, Redcare Pharmacy N.V. generated EUR 2.9 billion in revenues in 2025 and serves over 14 million active customers across seven European countries. The company offers more than 500,000 healthcare-related products, including OTC drugs, nutritional supplements, beauty and personal care items, and prescription drugs in Germany, Switzerland, and the Netherlands. Listed on the Frankfurt Stock Exchange (Prime Standard) since 2016, Redcare is part of the SDAX. For more details, view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Redcare Pharmacy Raises 2026 Guidance on Strong Rx Momentum
